醒脾养儿颗粒治疗小儿原发性夜间遗尿症的临床观察

发布时间：2018-06-22 02:42

本文选题：醒脾养儿颗粒 + 小儿　；参考：《中国药房》2017年06期

【摘要】：目的:观察醒脾养儿颗粒治疗小儿原发性夜间遗尿症的疗效和安全性。方法:97例原发性夜间遗尿症患儿随机分为对照组(46例)和观察组(51例)。对照组患儿给予消旋山莨菪碱片0.5 mg/(kg·d),口服,每日1次+维生素B1片10 mg,口服,每日3次+谷维素片10 mg,口服,每日3次+睡前30 min口服盐酸甲氯芬酯胶囊0.1 g,口服,每日1次。观察组患儿在对照组治疗的基础上加服醒脾养儿颗粒5~6岁0.4 g,7~14岁0.6 g,每日3次。两组均连续治疗4周。观察两组患儿的临床疗效,治疗前后肾阳虚症状积分、唤醒阈、膀胱容量、膀胱容量壁厚指数(BVWI)、遗尿频率、血清精氨酸加压素(AVP)、环磷酸腺苷(c AMP)、环磷酸鸟苷(c GMP)、c AMP/c GMP,复发率及不良反应发生情况。结果:观察组患儿总有效率显著高于对照组,差异有统计学意义(P0.01)。治疗后,两组患儿肾阳虚症状积分、唤醒阈、BVWI、遗尿频率、血清c GMP均显著低于同组治疗前,且观察组显著低于对照组;两组患儿膀胱容量、血清AVP、c AMP、c AMP/c GMP均显著高于同组治疗前,且观察组显著高于对照组,差异均有统计学意义(P0.01)。治疗3个月后,两组总有效患儿复发率比较,差异无统计学意义(P0.05);治疗6个月后,观察组总有效患儿复发率显著低于对照组,差异有统计学意义(P0.01)。两组患儿不良反应发生率比较,差异无统计学意义(P0.05)。结论:在常规治疗的基础上,醒脾养儿颗粒治疗小儿原发性夜间遗尿症的疗效和安全性均较好,可改善患儿肾阳虚症状及唤醒阈,提高患儿的膀胱容量和血清AVP。
[Abstract]:Objective: to observe the efficacy and safety of Xingpi Yanger granule in treating children with primary nocturnal enuresis. Methods 97 children with primary nocturnal enuresis were randomly divided into control group (46 cases) and observation group (51 cases). The control group was treated with anisodamine tablets for 0.5 mg/ (kg d), vitamin B1 10 mg once a day, oryzanol 10 mg 3 times a day, oral methylclophanate capsules 0.1 g 3 times a day 30 min before bedtime, once a day. On the basis of treatment in control group, the children in the observation group were treated with Xingpi Yanger granule at the age of 6 years, 0.4 g / 7 and 14 years old, 0.6 g / d, 3 times a day. Both groups were treated continuously for 4 weeks. The clinical efficacy, symptom score, arousal threshold, bladder volume wall thickness index (BVWI) and enuresis frequency of the two groups were observed before and after treatment. Serum arginine vasopressin (AVP), cyclic adenosine monophosphate (camp), cyclic guanosine monophosphate (cGMP), c AMP / c GMP, recurrence rate and adverse reactions. Results: the total effective rate in the observation group was significantly higher than that in the control group (P 0.01). After treatment, the scores of symptoms of kidney-yang deficiency, wake-up threshold, enuresis frequency, serum cGMP in both groups were significantly lower than those before treatment in the same group, and the bladder volume in the observation group was significantly lower than that in the control group, and the bladder volume in the two groups was significantly lower than that in the control group. The serum levels of AMPP / cGMP in the observation group were significantly higher than those in the control group (P0.01), and those in the observation group were significantly higher than those in the control group (P0.01). After 3 months of treatment, there was no significant difference in the recurrence rate between the two groups (P0.05); after 6 months of treatment, the total effective recurrence rate of the observation group was significantly lower than that of the control group, the difference was statistically significant (P0.01). There was no significant difference in the incidence of adverse reactions between the two groups (P0.05). Conclusion: on the basis of routine treatment, Xingpi Yanger granule is effective and safe in treating children with primary nocturnal enuresis, which can improve the symptoms of kidney-yang deficiency and arousal threshold, increase the bladder capacity and serum AVP in children.
【作者单位】：黔南布依族苗族自治州中医医院儿科;
【基金】：贵州省中医药、民族医药科学技术研究课题(No.QZYY2013-14) 黔南州科技计划项目(No.黔南科合字2013010)
【分类号】：R272.6

【参考文献】